N. Castagnoli Jr., J. P. Petzer, S. Steyn, K. Castagnoli, J. F. Chen, M. A. Schwarzschild and C. J. Van der Schyf, “Monoamine Oxidase B Inhibition and Neuroprotection: Studies on Selective Adenosine A2A Receptor Antagonists,” Neurology, Vol 61, No. 11, 2003, pp. S62-S68. doi:10.1212/01.WNL.0000095215.97585.59

has been cited by the following article:

• TITLE: Motor Effects of 1,3-Disubstituted 8-Styrylxanthines as A1 and A2 Adenosine-Receptor Antagonists in Rats

  AUTHORS: Ilhuicamina Daniel Limón-Pérez de León, María del Carmen Parra-Cid, Alejandro Muñoz-Zurita, Saúl Alejandro Merino-Contreras, Sara Montiel-Smith, Socorro Meza-Reyes, Gerardo Ramírez-Mejía, Jesús Sandoval-Ramírez

  KEYWORDS: Xantines; Adenosine Receptors Antagonists; Turning Behavior; Anti-Parkinsonian Drugs

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.3, June 4, 2013

  ABSTRACT: A series of 1,3-substituted 8-styrylxanthines (11a-d) was synthesized, under chemo- and regioselective conditions, in a good overall yield. The compounds showed affinity towards both A1 and A2A-adenosine receptors by radioligand binding by means of in vitro assays. The (E)-3-ethyl-1-propyl-8-styrylxanthine (11a) showed the greatest affinity towards the A2A receptor, whereas (E)-3-pentyl-1-propyl-8-styrylxanthine (11d) showed the greatest affinity for the A1 receptor. When the 8-styrylxanthines 11a (A15Et) and 11c (A15Bu) were administrated in rats, which were previously injured with 6-hydroxydopamine at the substantia nigra pars compacta (SNc), the turning behavior decreased 50%. Based on these results we propose to A15Et as a potential compound to treat some symptoms of Parkinson’s disease.